Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIGMON

Gabather AB has partnered with MINDIG (https://mindig.io/company/), a French company with an interdisciplinary team of data scientists, neurologists, and software engineers collaboratively pushing the boundaries of Electroencephalographic (EEG) analysis and neuroscience. The team at MINDIG will conduct a comprehensive and in-depth analysis of the extensive EEG data generated during the EEG/fMRI target engagement study with our lead candidate, GT-002, involving human healthy volunteers. Leveraging MINDIG's top-tier expertise and extensive experience in human brain analysis, this collaboration aims to optimize and extend the value derived from the data. The processing of the data is anticipated to be completed within a timeframe of 2 weeks.

" We are delighted to have found such a competent and excellent partner that shares our vision of utilizing brain activity data in the development of novel therapeutics capable of making a positive impact on the lives of patients and their families ." says Michael-Robin Witt, CEO of Gabather. 

Om Gabather

Gabathers affärsidé är att utveckla nya läkemedel för att behandla sjukdomar inom det centrala nervsystemet med nya verkansvägar, större träffsäkerhet och mindre biverkningar.

Webbplats
www.gabather.com
Bransch
Sjukvård

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn GABA ISIN-kod SE0010869552 Certified Adviser Corpura Fondkommission AB

IR-Kontakt

Michael-Robin Witt VD [email protected] 073-687 28 39